Manchester, UK – 3 December 2012 –Phagenesis Ltd, the global leader in the treatment of dysphagia, has won the Bionow Healthcare Project of the Year 2012 award. The award follows the launch of its first product, Phagenyx®, a medical device that treats dysphagia (difficulty swallowing) after stroke, in October.
Around half of stroke patients suffer with dysphagia1, a condition that is usually managed with puréed diet and tube feeding.
The award was sponsored by TRUSTECH, the North West NHS Innovation Service and entrants were judged on the impact of the product on the clinical problem it addresses, the quality of the product and the degree of innovation. The award was highly contested but on presenting the award Dr. Richard Deed, Innovation Unit Manager of TRUSTECH, said the judge’s decision was unanimous.
The award was collected by Dr. Conor Mulrooney, Chief Operating Officer at Phagenesis®.
Daniel Green, CEO of Phagenesis, said: “We are very pleased that Phagenesis® has won this award. We have seen so much development in the company over the past year. Dysphagia is an area of unmet medical need and we feel that this award reflects our device and the work that we are doing to address this.”
The annual awards dinner was attended by more than 280 executives from the biomedical sector.
Geoff Davison, CEO of Bionow, said: ‘The winners represent the cream of one of the leading clusters of biomedical businesses in the UK.”
Phagenesis® is developing the first clinically proven treatment for dysphagia, a debilitating and often lethal condition in which the patient’s ability to swallow is damaged. Dysphagia can lead to the inhalation of solids or liquids followed by pneumonia. Sufferers may face being fed through a tube indefinitely, reduced life expectancy and many are treated for depression. Phagenesis raised a £2 million Series A financing in 2010 and a €7m financing in 2011.
Bionow is a specialist business development and services company focused on the biomedical industry in the North of England and has over 160 members.